Delivery Order SPE2DP20D0002-SPE2DP25F109S
Award Date 9/8/25
Potential Completion Date 9/23/25
Potential Value $826K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order valued at $660,627.72 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on August 12, 2025, with an ultimate completion date of August 26, 2025. This firm-fixed-price delivery order, issued without set-aside designation, represents continued federal procurement from Teva as a critical supplier of vaccines and pharmaceutical products to military immunization programs. The contract will be performed at...
- The U.S. Department of Defense's Medical Supply Chain awarded a $660,627.72 firm-fixed-price delivery order to Teva Pharmaceuticals USA, Inc. on September 8, 2025, for the supply of Adenovirus Type 4 vaccine. The contract, issued without set-aside designation, is scheduled for completion by September 23, 2025, with performance conducted at Teva's facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed price delivery order against the Defense Logistics Agency Troop Support Medical for $2,443,150.08 to supply adenovirus type 4 vaccine. The place of performance is Parsippany, New Jersey and the completion date is December 19, 2023. This delivery order supports the military immunization programs of the Defense Logistics Agency Troop Support Medical by providing the requested adenovirus type 4 vaccine. Teva Pharmaceuticals USA, Inc. is a...
- Teva Pharmaceuticals USA, Inc. has been awarded a firm fixed price delivery order valued at one hundred fifty-two thousand six hundred ninety-six dollars and eighty-eight cents ($152,696.88) by the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support immunization programs of the military. Teva Pharmaceuticals USA, Inc. is a manufacturer of pharmaceutical products located in...
- Teva Pharmaceuticals USA, Inc. was awarded a Firm Fixed Price Delivery Order by the Defense Logistics Agency Troop Support Medical to provide Adenovirus Type 4 vaccine in Parsippany, New Jersey. The contract has a potential value of $146,823.93 and a completion date of December 20, 2022. Teva is a foreign-owned, for-profit manufacturer that has a history of providing pharmaceutical products, including vaccines and respiratory treatments, to various federal customers such as the Department of...
- Teva Pharmaceuticals USA, Inc. was awarded a $542,988 delivery order against the Defense Logistics Agency Troop Support Medical indefinite-delivery/indefinite-quantity contract to provide adenovirus type 4 to the Department of Defense. The firm fixed price order calls for Teva to deliver the pharmaceutical product to a location in Parsippany, New Jersey between August 19 and 25, 2020. No subcontractors or set aside designations were identified. The Defense Logistics Agency Troop Support...